source
- Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung diseaseRoivant Sciences reported that its inhaled candidate mosliciguat has successfully completed a Phase 2 trial in patients with interstitial lung disease. The study met its primary endpoint, showing a…
- Moderna and Merck’s personalized mRNA cancer vaccine success spurs industry shift to faster, smaller-scale productionAfter mastering large‑scale mRNA manufacturing during the COVID‑19 pandemic, the sector is now turning its attention to delivering individualized vaccines to patients quickly. The recent clinical…